[1] Ibrahim S, Kamath B, Loomes K, et al. Cholestatic liver diseases of genetic etiology: advances and controversies. Hepatology, 2022, 75(6): 1627-1646. [2] Kohut TJ, Gilbert MA, Loomes KM. Alagille syndrome: a focused review on clinical features, genetics, and treatment. Semin Liver Dis, 2021, 41(4): 525-537. [3] Kamath B, Munoz P, Bab N, et al. A longitudinal study to identify laboratory predictors of liver disease outcome in Alagille syndrome. J Pediatr Gastroenterol Nutr, 2010, 50(5): 526-530. [4] O'Hare M, Arboleda-Velasquez J. Notch signaling in vascular endothelial and mural cell communications. Cold Spring Harb Perspect Med, 2022, 12(9): a041159. [5] Liu XG, Wei HJ, Liu P, et al. Alagille 综合征的临床特点与基因突变分析. Zhonghua Yi Xue Za Zhi, 2021, 101(31): 2454-2459. [6] 陈玉霞, 詹学, 李蜀媛. Alagille综合征13例患儿特征分析. 中华实用儿科临床杂志. 2020, 35(19): 1468-1471. [7] Vander Does A, Levy C, Yosipovitch G. Cholestatic itch: our current understanding of pathophysiology and treatments. Am J Clin Dermatol, 2022, 23(5): 647-659. [8] Loomes K, Spino C, Goodrich N, et al. Bone density in children with chronic liver disease correlates with growth and cholestasis. Hepatology, 2019, 69(1): 245-257. [9] Kamath BM, Ye W, Goodrich NP, et al. Outcomes of childhood cholestasis in alagille syndrome: results of a multicenter observational study. Hepatol Commun, 2020, 4(3): 387-398. [10] Andrews A, Putra J. Central hepatic regenerative nodules in alagille syndrome: a clinicopathological review. Fetal Pediatr Pathol, 2021, 40(1): 69-79. [11] Schindler E, Gilbert M, Piccoli D, et al. Alagille syndrome and risk for hepatocellular carcinoma: need for increased surveillance in adults with mild liver phenotypes. Am J Med Genet A, 2021, 185(3): 719-731. [12] Ennaifer R, Ben Farhat L, Cheikh M, et al. Focal liver hyperplasia in a patient with Alagille syndrome: diagnostic difficulties. A case report. Int J Surg Case Rep, 2016, 25: 55-61. [13] Fabris L, Fiorotto R, Spirli C, et al. Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. Nat Rev Gastroenterol Hepatol, 2019, 16(8): 497-511. [14] Li ZD, Abuduxikuer K, Wang L, et al. Defining pathogenicity of NOTCH2 variants for diagnosis of Alagille syndrome type 2 using a large cohort of patients. Liver Int, 2022, 42(8): 1836-1848. [15] Zhang W, Zhao X, Huang J, et al. Alagille syndrome: an uncommon cause of intrahepatic cholestasis in adults. Rev Esp Enferm Dig. 2019, 111(4): 323-326. [16] Wang K, Tiao G, Bass L, et al. Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis. Hepatology, 2017, 65(5): 1645-1654. [17] 檀玉乐, 朱志军, 孙丽莹, 等. 儿童肝移植治疗Alagille综合征的单中心经验. 2022, 13(1): 61-66. [18] Kriegermeier A, Taylor S. Apical sodium-dependent bile acid transporter inhibition in children with Alagille syndrome. Lancet, 2021, 398(10311): 1544-1545. [19] Shirley M. Maralixibat: first approval. Drugs, 2022, 82(1): 71-76. [20] Deeks E. Odevixibat: first approval. Drugs, 2021, 81(15): 1781-1786. [21] Karpen S J, Kelly D, Mack C, et al. Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int, 2020, 14(5): 677-689. |